A 23-year-old man completes 6 months of treatment for drug-sensitive pulmonary TB. His treatment included rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months. He was fully adherent. At treatment completion, he is asymptomatic. His chest X-ray shows residual fibrotic changes but no active disease. Sputum smears are negative. What is the most appropriate management?
A 44-year-old woman with a history of pulmonary tuberculosis treated 8 years ago presents with progressive dyspnoea on exertion. Examination reveals reduced breath sounds and stony dullness to percussion in the right lower zone. Chest X-ray shows a large right-sided pleural effusion. Pleural fluid analysis reveals: protein 45 g/L, LDH 890 U/L, glucose 1.8 mmol/L, pH 7.28, lymphocyte predominance. Pleural fluid culture is negative at 72 hours. What is the most appropriate next investigation?
A 7-year-old boy presents with fever, headache, and neck stiffness. LP shows: white cell count 3,200/mm³ (95% neutrophils), protein 3.5 g/L, glucose 1.5 mmol/L (plasma glucose 6.0 mmol/L). Gram stain shows Gram-negative diplococci. He is treated with IV ceftriaxone. Blood culture at 48 hours grows Neisseria meningitidis with MIC to penicillin of 0.25 mg/L. His clinical condition has improved. What is the most appropriate modification to antibiotic therapy?
A 50-year-old man with multidrug-resistant tuberculosis (resistant to rifampicin and isoniazid) is being treated with a second-line regimen including levofloxacin, bedaquiline, linezolid, cycloserine, and ethambutol. After 3 months of treatment, he develops progressive hearing loss and tinnitus. Audiometry confirms bilateral high-frequency sensorineural hearing loss. What is the most likely causative drug and appropriate management?
A 19-year-old university student is diagnosed with meningococcal meningitis confirmed by blood culture growing Neisseria meningitidis serogroup W. He shares a house with 5 other students. Public health authorities are contacted. Which of the following household contacts requires antibiotic prophylaxis?
A 65-year-old woman presents with a 3-day history of fever, confusion, and right-sided weakness. MRI brain shows multiple ring-enhancing lesions in the left frontal and parietal lobes with surrounding oedema. Lumbar puncture reveals: white cell count 180/mm³ (70% lymphocytes, 30% neutrophils), protein 2.1 g/L, glucose 2.5 mmol/L (plasma glucose 5.8 mmol/L). She immigrated from India 6 months ago. What is the most appropriate initial investigation to confirm the diagnosis?
A 34-year-old pregnant woman at 16 weeks gestation is identified as a contact of her brother who has smear-positive pulmonary tuberculosis. She is asymptomatic and her chest X-ray with abdominal shielding is normal. Her interferon-gamma release assay is positive. She has no history of previous TB treatment. What is the most appropriate management?
A 28-year-old man presents to the emergency department with sudden onset severe headache, fever of 39.2°C, and confusion. He has multiple small pustular lesions on his hands and face. Lumbar puncture shows: white cell count 2,400/mm³ (90% neutrophils), protein 2.8 g/L, glucose 1.8 mmol/L (plasma glucose 6.2 mmol/L). Gram stain shows Gram-positive cocci in clusters. He keeps pigeons as a hobby. What is the most appropriate empirical antibiotic therapy?
A 58-year-old man with chronic kidney disease (eGFR 35 mL/min/1.73m²) is diagnosed with drug-sensitive pulmonary tuberculosis. He is started on standard four-drug therapy. Three weeks into treatment, he develops painful paraesthesia in both feet and difficulty walking. Examination reveals reduced ankle reflexes and impaired vibration sense distally. What is the most likely cause and appropriate management?
A 22-year-old woman presents with a 12-hour history of severe headache, photophobia, and neck stiffness. Lumbar puncture reveals: opening pressure 28 cmH2O, CSF white cell count 850/mm³ (85% lymphocytes), protein 1.2 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). Gram stain is negative. She had a similar episode 2 years ago that resolved spontaneously. What is the most likely diagnosis?
Explanation: ***Discharge from follow-up with written advice about recurrence symptoms*** - For a patient who has completed a standard **6-month course** for drug-sensitive TB and is **asymptomatic** with negative smears, routine clinical or radiological follow-up is not required according to **NICE guidelines**. - The priority is to provide **safety-netting** by educating the patient on the symptoms of **relapse** so they can self-refer if necessary. *Extend treatment with rifampicin and isoniazid for a further 3 months* - Extending treatment is unnecessary because the patient was **fully adherent** and successful completion of the **standard regimen** results in high cure rates. - **Residual fibrotic changes** on X-ray are common post-infection and do not indicate active disease requiring additional therapy. *Arrange follow-up chest X-ray in 3 months and annually for 2 years* - Routine **surveillance imaging** is not cost-effective or clinically recommended for uncomplicated, drug-sensitive pulmonary TB in patients who are **clinically well**. - Evidence shows that relapse is typically detected through **symptomatic presentation** rather than routine radiographic monitoring. *Commence isoniazid monotherapy for 3 months to prevent relapse* - There is no clinical indication for **isoniazid monotherapy** following a completed full course of treatment as it does not further reduce **relapse risk**. - Monotherapy after incomplete bacterial clearance would risk the development of **drug-resistant TB**. *Arrange bronchoscopy to exclude residual infection* - **Bronchoscopy** is an invasive procedure that is not indicated when **sputum smears are negative** and the patient is asymptomatic. - **Negative sputum smears** at the end of treatment are sufficient to confirm the success of the therapy in this clinical context.
Explanation: ***Pleural fluid adenosine deaminase (ADA) level*** - The patient's pleural fluid analysis reveals a **lymphocytic exudate** with **low glucose** (1.8 mmol/L) and **low pH** (7.28), coupled with a history of **pulmonary tuberculosis**, which are classic indicators of **tuberculous pleuritis**. - **Pleural fluid ADA** is a highly sensitive and specific biomarker for **tuberculous pleuritis**, providing a rapid and cost-effective diagnostic tool before resorting to more invasive procedures. *CT-guided pleural biopsy for histology and TB culture* - While a **pleural biopsy** is highly diagnostic, it is a more invasive procedure compared to a biochemical fluid analysis like ADA measurement. - This investigation is typically considered if less invasive tests are inconclusive or when there is a need for tissue diagnosis, for instance, to rule out other pathologies or assess pleural thickening. *Video-assisted thoracoscopic surgery (VATS) with pleural biopsy* - **VATS** with biopsy is considered the **gold standard** for pleural disease diagnosis due to its ability to obtain adequate tissue for pathology, but it is a **surgical procedure** with associated risks. - It is usually reserved for cases where less invasive diagnostic methods have failed to provide a definitive diagnosis. *Repeat pleural fluid culture at 6 weeks* - Waiting for **Mycobacterium tuberculosis culture** results can take up to 6-8 weeks due to the slow growth rate of the organism, leading to significant delays in diagnosis and treatment initiation. - Rapid diagnostic tests like **ADA** are preferred as initial steps to guide prompt management decisions. *Pleural fluid cytology for malignant cells* - Although malignancy can cause a **lymphocytic exudative effusion**, the combination of **very low glucose** and **low pH** in a patient with a history of TB points more strongly towards **tuberculous pleuritis**. - While cytology is important to exclude malignancy, the immediate diagnostic priority, given the specific fluid characteristics and history, is to confirm or rule out active TB.
Explanation: ***Switch to intravenous benzylpenicillin for a total of 7 days***- **Benzylpenicillin** is the definitive treatment of choice for **Neisseria meningitidis** when the **MIC is ≤1 mg/L** (typically ≤0.5 mg/L in many guidelines), even with reduced susceptibility.- It provides excellent **CSF penetration** during inflammation and is a **narrower-spectrum**, highly **bactericidal** agent, adhering to antimicrobial stewardship principles once sensitivities are known.*Continue ceftriaxone for a total of 7 days*- While effective as empiric therapy, **ceftriaxone** is a broader-spectrum antibiotic; **antimicrobial stewardship** dictates switching to the more specific **benzylpenicillin** once *Neisseria meningitidis* is confirmed sensitive to penicillin.- Continuing ceftriaxone is less ideal when a narrower-spectrum agent like penicillin can be used effectively for the identified pathogen with an acceptable MIC.*Add rifampicin to ceftriaxone and continue for 7 days*- **Rifampicin** is primarily used for **chemoprophylaxis** to eliminate nasopharyngeal carriage in close contacts, not as an add-on for treating active meningococcal meningitis.- There is no evidence that adding rifampicin improves clinical outcomes in the acute treatment of **meningococcal meningitis** in this scenario.*Switch to oral ciprofloxacin to complete 7 days of therapy*- **Bacterial meningitis** requires high-dose **intravenous antibiotics** to achieve adequate **cerebrospinal fluid (CSF) concentrations** and effectively treat the infection.- **Oral ciprofloxacin** is typically used for **prophylaxis** of contacts and is generally insufficient for treating established meningitis due to inadequate systemic and CSF penetration.*Continue ceftriaxone for 14 days as there is reduced penicillin susceptibility*- The **MIC of 0.25 mg/L** for penicillin, while indicating reduced susceptibility, is still within the range considered treatable with standard high-dose **benzylpenicillin** for meningitis.- The standard duration for uncomplicated **meningococcal meningitis** is **7 days**; extending treatment to 14 days is unnecessary and not indicated solely based on this MIC.
Explanation: ***Linezolid; stop linezolid and monitor for improvement*** - **Linezolid** is a known cause of **mitochondrial toxicity**, which commonly presents as **bilateral high-frequency sensorineural hearing loss** and tinnitus, especially during prolonged treatment for MDR-TB. - The management involves **immediate cessation of linezolid** to prevent further auditory damage, although the hearing loss can often be irreversible. *Cycloserine; reduce dose by 50% and check serum levels* - **Cycloserine** is primarily associated with **neuropsychiatric side effects**, such as psychosis, depression, and seizures, due to its CNS penetration. - It is not a recognized cause of **ototoxicity** or hearing loss, so dose adjustment for this symptom would be inappropriate. *Bedaquiline; continue treatment as hearing loss is reversible* - **Bedaquiline**'s main adverse effects include **QT prolongation** and potential **hepatotoxicity**. - It does not cause hearing loss, and continuing a drug known to cause ototoxicity would be medically incorrect. *Ethambutol; stop immediately and perform MRI brain* - **Ethambutol** characteristically causes **optic neuritis**, leading to decreased visual acuity and red-green color blindness. - It does not cause high-frequency sensorineural hearing loss, and an **MRI brain** is not indicated for drug-induced ototoxicity. *Levofloxacin; switch to moxifloxacin which has lower ototoxicity* - **Fluoroquinolones** like levofloxacin are rarely implicated in ototoxicity; their more common severe adverse effects include **tendon rupture** and **QT prolongation**. - Switching to **moxifloxacin** would not resolve the hearing loss as both fluoroquinolones share similar (very low) ototoxicity profiles.
Explanation: ***All household contacts regardless of duration of exposure in the 10 days before symptom onset***- Chemoprophylaxis is indicated for all individuals residing in the **same household** as a case of **Neisseria meningitidis** to eradicate carriage and prevent secondary cases.- Guidelines generally define the at-risk period as the **7 to 10 days** prior to the onset of symptoms, and all household members are treated due to the high risk of **nasopharyngeal colonization**.*All household contacts who had more than 8 hours contact with the case in the 7 days before symptom onset*- While the **7-day window** is relevant, the **8-hour threshold** typically applies to non-household contacts, such as those in a workplace or school environment.- **Household members** are considered high-risk by default and do not need to meet a specific hourly quota to qualify for antibiotics like **ciprofloxacin**.*Only household contacts who had direct exposure to respiratory secretions in the 24 hours before diagnosis*- Direct exposure to **respiratory secretions** (e.g., mouth-to-mouth resuscitation) is the criterion used for **healthcare workers**, not household contacts.- The risk window for family or housemates is much wider than **24 hours**, as the bacteria can be transmitted well before clinical diagnosis.*Only household contacts who are unvaccinated against meningococcus*- **Antibiotic prophylaxis** is required for all close contacts regardless of their **vaccination status**, as vaccines do not provide 100% protection against colonization.- While a vaccine may be offered as follow-up if the serogroup is covered (like **serogroup W**), it does not replace the immediate need for **chemoprophylaxis**.*All household contacts within 14 days of symptom onset who spent more than 1 hour in close contact*- A **14-day window** exceeds the standard incubation and transmission period monitored for immediate antibiotic intervention, which is usually capped at **7 to 10 days**.- The **1-hour contact** rule is not a standard guideline for determining prophylaxis; focus remains on the **intensity** of the living environment rather than specific minute counts.
Explanation: ***CSF polymerase chain reaction for Mycobacterium tuberculosis*** - The patient's presentation with **fever, confusion, focal neurological deficit**, **ring-enhancing lesions**, **lymphocytic pleocytosis**, **high CSF protein**, **low CSF glucose**, and recent immigration from **India** strongly suggests **tuberculous meningitis** or **CNS tuberculomas**. - **CSF PCR for M. tuberculosis** offers high **specificity** and **rapid results**, making it the most appropriate and timely initial investigation to confirm the diagnosis in this highly suspicious clinical context.*CSF Ziehl-Neelsen stain and TB culture* - **Ziehl-Neelsen (ZN) stain** has a very **low sensitivity** (10-20%) for detecting acid-fast bacilli in CSF, leading to frequent false negatives in tuberculous meningitis. - While **TB culture** is the gold standard, it requires **6-8 weeks** for results, which is too long for initial diagnosis and urgent treatment initiation in a severe neurological infection.*Serum toxoplasma serology* - **Toxoplasmosis** typically affects **immunocompromised individuals** (e.g., HIV/AIDS), a status not indicated for this patient, and often presents with **normal CSF glucose**. - While it can cause **ring-enhancing lesions**, the combination of profound **low CSF glucose**, **high protein**, and the epidemiological factor points away from toxoplasmosis as the primary concern.*Brain biopsy for histopathology and culture* - **Brain biopsy** is an **invasive procedure** with associated risks, generally reserved for cases where less invasive diagnostic methods, such as CSF analysis and imaging, are inconclusive. - It is not the appropriate **initial** investigation when a highly suggestive diagnosis, like tuberculous meningitis, can be confirmed more safely and rapidly with CSF studies.*CSF bacterial culture and fungal culture* - The CSF analysis showing a **lymphocytic predominance** (70% lymphocytes) combined with a **subacute presentation** makes acute bacterial meningitis less likely to be the primary diagnosis. - While **fungal infections** can cause similar CSF findings and ring-enhancing lesions, the strong epidemiological link to **tuberculosis** makes specific testing for *Mycobacterium tuberculosis* the most targeted and appropriate initial step.
Explanation: ***Start isoniazid and pyridoxine immediately and continue throughout pregnancy*** - This patient has **latent tuberculosis infection (LTBI)**, diagnosed by a **positive IGRA** and normal chest X-ray following recent contact with a positive case. Current guidelines recommend treatment during pregnancy for those with recent exposure to prevent progression to active disease. - **Isoniazid (INH)** is the preferred drug for LTBI in pregnancy, given for 6-9 months, and **pyridoxine (vitamin B6)** is co-administered to prevent **isoniazid-induced peripheral neuropathy**. *Defer treatment until after delivery and breastfeeding are completed* - Deferring treatment significantly increases the risk of **reactivation** to active TB during the postpartum period, which is a high-risk time due to physiological stress and potential immunosuppression. - Current guidelines favor treating LTBI in pregnancy, especially with recent exposure, to protect both the mother and the **fetus** from the greater risks associated with active disease. *Start rifampicin and isoniazid for 3 months after delivery* - While this is a shorter alternative regimen for LTBI, initiating it **postpartum** is inappropriate when a higher risk of progression is present during pregnancy. - Delaying treatment ignores the **recent contact history** and the high-risk status, which necessitates prompt intervention to prevent active TB development during pregnancy. *Commence four-drug anti-tuberculous therapy immediately* - This intensive regimen is reserved for **active TB disease** and is not indicated for **latent infection** with a normal chest X-ray and no symptoms. - Using four drugs unnecessarily increases the risk of **drug toxicity** and side effects for both the mother and the developing fetus when only LTBI is present. *Monitor with monthly chest X-rays and start treatment only if she develops active TB* - **Monthly chest X-rays** involve unnecessary radiation exposure to the fetus, even with shielding. - This approach is reactive and fails to prevent the morbidity and mortality associated with the progression to **active TB**, which is the primary goal of LTBI treatment in high-risk individuals.
Explanation: ***Intravenous ceftriaxone and vancomycin*** - The presence of **Gram-positive cocci in clusters** in the CSF, along with **pustular skin lesions**, strongly suggests **Staphylococcus aureus** meningitis, requiring empirical coverage for both MSSA and **MRSA**. - **Ceftriaxone** provides broad Gram-negative and MSSA coverage, while **vancomycin** is essential to cover potential **Methicillin-resistant Staphylococcus aureus (MRSA)** until sensitivities are available. *Intravenous benzylpenicillin and gentamicin* - This combination is not standard for staphylococcal meningitis as **benzylpenicillin** is ineffective against most strains of **Staphylococcus aureus** due to beta-lactamase production. - **Gentamicin** has poor **blood-brain barrier** penetration and is insufficient as a primary agent for meningitis. *Intravenous meropenem* - While **meropenem** provides broad-spectrum coverage, it lacks adequate activity against **MRSA**, which must be considered given the Gram-positive cocci in clusters. - It is generally reserved for **multi-drug resistant** Gram-negative infections or as a second-line agent in specific clinical scenarios. *Intravenous ceftriaxone and doxycycline* - **Doxycycline** might be considered if **psittacosis** (Chlamydia psittaci) was suspected due to pigeon exposure, but the CSF profile shows **neutrophilic pleocytosis** and cocci, diagnostic of bacterial meningitis. - It does not provide the necessary **bactericidal** activity or coverage required for a confirmed staphylococcal central nervous system infection. *Intravenous flucloxacillin and rifampicin* - **Flucloxacillin** is the drug of choice for **MSSA**, but it is inappropriate for empirical use here because it cannot cover **MRSA**. - **Rifampicin** is used as an adjunct in specific staphylococcal infections but should never be used as **monotherapy** or first-line empirical treatment without a backbone like vancomycin.
Explanation: ***Isoniazid-induced peripheral neuropathy; add pyridoxine and continue treatment***- **Isoniazid (INH)** interferes with **pyridoxine (Vitamin B6)** metabolism, leading to a distal symmetric polyneuropathy and painful **paraesthesia**, especially in patients with **chronic kidney disease**. - Treatment involves supplemental **pyridoxine** (usually 10-50mg daily), which addresses the deficiency while allowing the essential TB therapy to continue.*Ethambutol toxicity; stop ethambutol immediately and check visual acuity*- **Ethambutol** is primarily associated with **optic neuritis**, causing decreased visual acuity and **red-green color blindness**, rather than peripheral nerve symptoms.- While it requires monitoring in renal impairment, it does not explain the loss of **ankle reflexes** or **vibration sense** in the feet.*Rifampicin-induced neuropathy; reduce rifampicin dose by 50%*- **Rifampicin** is not typically associated with **peripheral neuropathy**; its main side effects are **hepatotoxicity** and orange-colored body fluids.- Reducing the dose by 50% is inappropriate and risks developing **drug resistance** without addressing the metabolic cause of the neuropathy.*TB-related vasculitis; start prednisolone 40 mg daily*- While TB can cause immune-mediated phenomena, a symmetrical **sensory-motor neuropathy** following drug initiation is highly pathognomonic for **drug toxicity** rather than vasculitis.- **Prednisolone** is used for TB meningitis or pericarditis, but is not the first-line treatment for standard treatment-induced nerve damage.*Uraemic neuropathy due to worsening renal function; arrange urgent dialysis*- **Uraemic neuropathy** generally occurs in patients with end-stage renal disease (eGFR <15); this patient's **eGFR of 35** makes isoniazid toxicity a more likely acute cause.- The sudden onset three weeks after starting **anti-tubercular therapy** strongly correlates with medication side effects rather than a sudden failure of renal filtration.
Explanation: ***Viral meningitis*** - The CSF highlights a **lymphocytic pleocytosis** with a **normal glucose ratio** (CSF:plasma glucose ratio >0.5), which is the classic profile for a viral etiology. - The history of a **spontaneous resolution and recurrence** is highly characteristic of **HSV-2**, often referred to as **Mollaret’s meningitis**. *Tuberculous meningitis* - Typically presents with a **subacute onset** over weeks and significantly **lower CSF glucose** (usually <50% of plasma glucose). - The CSF protein in tuberculous cases is usually **markedly elevated** (often >1.5 g/L), much higher than seen in this patient. *Partially treated bacterial meningitis* - While it can show a shift toward lymphocytes, it usually still demonstrates a **neutrophil predominance** or significantly **depressed glucose levels**. - This diagnosis requires a history of **antibiotic use** prior to the lumbar puncture, which is not mentioned here. *Neurosarcoidosis* - This condition typically follows a **chronic or relapsing-remitting course** rather than an acute 12-hour presentation of meningism. - It is usually associated with other **systemic manifestations** like hilar lymphadenopathy, uveitis, or cranial nerve palsies. *Listeria monocytogenes meningitis* - Although it can present with a lymphocytic picture, it primarily affects **immunocompromised individuals** or those over the age of 50. - It typically causes a more severe clinical picture with **lower glucose** and would not resolve spontaneously without treatment.
Get full access to all questions, explanations, and performance tracking.
Start For Free